Factive tablet receives marketing approval from Health Canada

Published: 2004-03-17 06:57:00

Updated: 2004-03-17 06:57:00

GenomeTherapeutics Corporation announced on March 12 that it has received marketing approval for Factive (gemifloxacin mesylate) for the treatment of acute bacterial exacerbations of chronic bronchitis from the Therapeutic Products Directorate of health Canada.

Factive tablet is an orally ad...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK